The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016.

ABSTRACT:

Background

Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses.

Methods

We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged < 5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the < 1-year age group, by 3-month intervals until 2 years, and then 12 monthly intervals to < 5 years for medically and non-medically att

SUBMITTER: Moyes J 

PROVIDER: S-EPMC10088270 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature